SHR-1701

Modify Date: 2024-04-03 10:48:59

Use of SHR-1701

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].

Name	SHR-1701

Description	SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
In Vitro	SHR-1701 (10 μg/mL)可以抑制 TGF-β 信号通路，激活 PI3K/Akt/Erk 信号通路，挽救淋巴细胞恢复受损的肺癌患者外周血CD8+ T 细胞的抗肿瘤功能[1]。
References	[1]. Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36.

No Any Chemical & Physical Properties